SOPHiA GENETICS (SOPH) president awarded options, RSUs and corrects holdings

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken received new equity awards and corrected his reported share holdings. On April 2, 2026 he was granted options to buy 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.

He also received 431,211 restricted stock units, each representing one ordinary share, bringing his directly held ordinary shares to 703,121 after the grant. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.

The share options vest 25% on April 2, 2027 and then in equal monthly installments through April 2, 2030. This amended filing corrects a prior report that had understated his post-transaction ordinary share holdings.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Muken Ross

Role President

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	628,743	$0.00	--
Grant/Award	Ordinary Shares	431,211	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 628,743 shares (Direct); Ordinary Shares — 703,121 shares (Direct)

Footnotes (1)

Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 703,121 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Stock options granted: 628,743 options Option exercise price: $5.04 per share Option expiration: April 2, 2036 +5 more

8 metrics

Stock options granted 628,743 options Share options granted on April 2, 2026

Option exercise price $5.04 per share Exercise price for 628,743 options

Option expiration April 2, 2036 Expiration date of granted options

RSUs granted 431,211 RSUs Restricted stock units granted on April 2, 2026

Ordinary shares after grant 703,121 shares Amount beneficially owned following reported transaction

Initial vesting date April 2, 2027 25% of RSUs and options vest on this date

RSU vesting end date April 2, 2030 RSUs vest quarterly through this date

Option vesting end date April 2, 2030 Options vest monthly through this date

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, contingent right, vest, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"grant made under the Issuer's 2021 Equity Incentive Plan."

contingent right financial

"Each RSU represents a contingent right to receive one ordinary share of the Issuer"

vest financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

beneficially owned financial

"Amount of Securities Beneficially Owned Following Reported Transaction"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Form 4 Insider Transactions: What Each Field Means →

04/08/2026 - 08:47 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last)

(First)

(Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/02/2026		A		431,211⁽¹⁾	A	$0	703,121⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$5.04	04/02/2026		A		628,743		⁽³⁾	04/02/2036	Ordinary Shares	628,743	$0	628,743	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 703,121 ordinary shares.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did SOPHiA GENETICS (SOPH) report for Ross Muken?

Ross Muken received equity awards on April 2, 2026, including stock options and restricted stock units. These are compensation-related grants, not open-market purchases or sales, and increase his potential and actual ownership in SOPHiA GENETICS SA over a multi-year vesting period.

How many SOPHiA GENETICS (SOPH) options were granted to Ross Muken and at what price?

He was granted options for 628,743 ordinary shares at an exercise price of $5.04 per share. These options vest 25% on April 2, 2027, then monthly through April 2, 2030, and expire on April 2, 2036 if not exercised, subject to plan terms.

What RSU grant did Ross Muken receive from SOPHiA GENETICS (SOPH)?

He received 431,211 restricted stock units, each representing a right to one ordinary share. Twenty-five percent vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on his continued service with the company.

How many SOPHiA GENETICS (SOPH) ordinary shares does Ross Muken hold after this Form 4/A?

After the reported RSU grant, he beneficially owns 703,121 ordinary shares directly. The amended filing corrects a prior report that had shown only 431,211 ordinary shares, clarifying his true post-transaction ownership amount as of the reported date.

What does the Form 4/A amendment for SOPHiA GENETICS (SOPH) correct?

The amendment corrects the amount in the column for securities beneficially owned after the transaction. It was previously reported as 431,211 ordinary shares due to an error; the correct figure is 703,121 ordinary shares, reflecting the impact of the newly granted RSUs.

When do Ross Muken’s SOPHiA GENETICS (SOPH) options and RSUs vest?

Both awards start vesting on April 2, 2027. RSUs vest 25% then, with the rest quarterly through April 2, 2030. Options vest 25% on April 2, 2027 and then in equal monthly installments through April 2, 2030, assuming continued service.